Hitting the Golden TORget: Curcumin's Effects on mTOR Signaling

被引:37
作者
Beevers, Christopher S. [1 ]
Zhou, Hongyu [2 ]
Huang, Shile [3 ,4 ]
机构
[1] Ross Univ, Dept Pharmacol, Sch Med, Picard, Portsmouth, Dominica
[2] Chinese Acad Sci, Kunming Inst Bot, Kunming 650201, Yunnan Province, Peoples R China
[3] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71105 USA
[4] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA
关键词
Curcumin; mTOR; Akt; Cancer; Cell proliferation; Cell death; I CLINICAL-TRIAL; P70; S6; KINASE; MAMMALIAN TARGET; AMINO-ACID; TRANSLATION INITIATION; CELL-PROLIFERATION; AKT ACTIVATION; RAPAMYCIN; PHOSPHORYLATION; PROTEIN;
D O I
10.2174/1871520611313070004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The polyphenol natural product curcumin possesses a plethora of biological and pharmacological properties. For years, much interest has been placed in the development and use of curcumin and its derivatives for the prevention and treatment of cardiovascular, diabetic, and neurodegenerative diseases, as well as cancer. Increasing evidence suggests that curcumin displays amazing molecular versatility, and the number of its proposed cellular targets grows as the research continues. The mammalian target of rapamycin ( mTOR) is a master kinase, regulating cell growth/proliferation, survival, and motility. Dysregulated mTOR signaling occurs frequently in cancer, and targeting mTOR signaling is a promising strategy for cancer therapy. Recent studies have identified mTOR as a novel target of curcumin. Here we focus on reviewing current knowledge regarding the effects of curcumin on mTOR signaling for better understanding the anticancer mechanism of curcumin. The emerging studies of mTOR signaling and clinical studies on curcumin with cancer patients are also discussed here.
引用
收藏
页码:988 / 994
页数:7
相关论文
共 100 条
[31]   Regulation of eIF-4E BP1 phosphorylation by mTOR [J].
Hara, K ;
Yonezawa, K ;
Kozlowski, MT ;
Sugimoto, T ;
Andrabi, K ;
Weng, QP ;
Kasuga, M ;
Nishimoto, I ;
Avruch, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (42) :26457-26463
[32]   Curcumin: From ancient medicine to current clinical trials [J].
Hatcher, H. ;
Planalp, R. ;
Cho, J. ;
Tortia, F. M. ;
Torti, S. V. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2008, 65 (11) :1631-1652
[33]   Upstream and downstream of mTOR [J].
Hay, N ;
Sonenberg, N .
GENES & DEVELOPMENT, 2004, 18 (16) :1926-1945
[34]   mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events [J].
Holz, MK ;
Ballif, BA ;
Gygi, SP ;
Blenis, J .
CELL, 2005, 123 (04) :569-580
[35]  
Hosoi H, 1999, CANCER RES, V59, P886
[36]   Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity [J].
Huang, SL ;
Shu, LL ;
Easton, J ;
Harwood, FC ;
Germain, GS ;
Ichijo, H ;
Houghton, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (35) :36490-36496
[37]   Dysregulation of the TSC-mTOR pathway in human disease [J].
Inoki, K ;
Corradetti, MN ;
Guan, KL .
NATURE GENETICS, 2005, 37 (01) :19-24
[38]   Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive [J].
Jacinto, E ;
Loewith, R ;
Schmidt, A ;
Lin, S ;
Rüegg, MA ;
Hall, A ;
Hall, MN .
NATURE CELL BIOLOGY, 2004, 6 (11) :1122-U30
[39]  
Johnson SM, 2009, ANTICANCER RES, V29, P3185
[40]  
Johnston S R D, 2006, Int J Gynecol Cancer, V16 Suppl 2, P543, DOI 10.1111/j.1525-1438.2006.00692.x